{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:21:29Z","timestamp":1761060089769},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0149467","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T18:42:32Z","timestamp":1456857752000},"page":"e0149467","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Antiviral Activity of Approved and Novel Drugs against HIV-1 Mutations Evaluated under the Consideration of Dose-Response Curve Slope"],"prefix":"10.1371","volume":"11","author":[{"given":"Shuai","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daomin","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuoyi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwan","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,3,1]]},"reference":[{"issue":"9740","key":"ref1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0140-6736(10)60936-1","article-title":"Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study","volume":"376","author":"JSG Montaner","year":"2010","journal-title":"Lancet"},{"issue":"13","key":"ref2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"FJ Palella","year":"1998","journal-title":"New Engl J Med"},{"issue":"6510","key":"ref3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/373117a0","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection","volume":"373","author":"X Wei","year":"1995","journal-title":"Nature"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1086\/515304","article-title":"Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure","volume":"177","author":"V Miller","year":"1998","journal-title":"J Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1086\/313855","article-title":"Determinants of virological response to antiretroviral therapy: Implications for long-term strategies","volume":"30","author":"SG Deeks","year":"2000","journal-title":"Clinical Infectious Diseases"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMra025195","article-title":"HIV drug resistance","volume":"350","author":"F Clavel","year":"2004","journal-title":"N Engl J Med"},{"issue":"6756","key":"ref7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/44755","article-title":"Re-emergence of HIV after stopping therapy","volume":"401","author":"TW Chun","year":"1999","journal-title":"Nature"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"F59","DOI":"10.1097\/00002030-199905280-00001","article-title":"Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy","volume":"13","author":"PR Harrigan","year":"1999","journal-title":"Aids"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"CJ Petropoulos","year":"2000","journal-title":"Antimicrob Agents Ch"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1128\/AAC.37.5.1095","article-title":"Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group","volume":"37","author":"AJ Japour","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"ref11","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs","volume":"14","author":"L Shen","year":"2008","journal-title":"Nat Med"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaci.2008.05.033","article-title":"Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection","volume":"122","author":"L Shen","year":"2008","journal-title":"The Journal of allergy and clinical immunology"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.tips.2009.09.003","article-title":"A novel method for determining the inhibitory potential of anti-HIV drugs","volume":"30","author":"L Shen","year":"2009","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.2649","article-title":"A quantitative basis for antiretroviral therapy for HIV-1 infection","volume":"18","author":"BL Jilek","year":"2012","journal-title":"Nat Med"},{"issue":"20","key":"ref15","doi-asserted-by":"crossref","first-page":"11368","DOI":"10.1128\/JVI.01563-12","article-title":"A quantitative measurement of antiviral activity of anti-human immunodeficiency virus type 1 drugs against simian immunodeficiency virus infection: dose-response curve slope strongly influences class-specific inhibitory potential","volume":"86","author":"K Deng","year":"2012","journal-title":"J Virol"},{"issue":"6","key":"ref16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-198106060-00002","article-title":"Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models","volume":"6","author":"NH Holford","year":"1981","journal-title":"Clin Pharmacokinet"},{"issue":"18","key":"ref17","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1073\/pnas.1018360108","article-title":"Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance","volume":"108","author":"MES Sampah","year":"2011","journal-title":"P Natl Acad Sci USA"},{"issue":"4713","key":"ref18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.2992081","article-title":"Infection of HTLV-III\/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay","volume":"229","author":"S Harada","year":"1985","journal-title":"Science"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","article-title":"Characteristics of a human cell line transformed by DNA from human adenovirus type 5","volume":"36","author":"FL Graham","year":"1977","journal-title":"The Journal of general virology"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"X Wei","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"supplement","key":"ref21","article-title":"The Possible Effects of the Aggregation of the Molecules of Hemoglobin on its Dissociation Curves","volume":"40","author":"AV Hill","year":"1909","journal-title":"Physiology"},{"issue":"91","key":"ref22","doi-asserted-by":"crossref","first-page":"91ra63","DOI":"10.1126\/scitranslmed.3002304","article-title":"A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs","volume":"3","author":"L Shen","year":"2011","journal-title":"Science translational medicine"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jama.2014.8722","article-title":"Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel","volume":"312","author":"HF Gunthard","year":"2014","journal-title":"Jama"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2174\/157016212803901419","article-title":"Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection","volume":"10","author":"L Calza","year":"2012","journal-title":"Curr HIV Res"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7883\/yoken.JJID.2008.361","article-title":"The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation","volume":"61","author":"M Zhang","year":"2008","journal-title":"Japanese journal of infectious diseases"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"e54917","DOI":"10.1371\/journal.pone.0054917","article-title":"HIV drug resistance and its impact on antiretroviral therapy in Chinese HIV-infected patients","volume":"8","author":"H Xing","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/cid\/ciu590","article-title":"Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: a systematic review and meta-analysis","volume":"59","author":"H Liu","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"32","key":"ref28","doi-asserted-by":"crossref","first-page":"9538","DOI":"10.1021\/jp502687q","article-title":"Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations","volume":"118","author":"H Tzoupis","year":"2014","journal-title":"The journal of physical chemistry B"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/cbdd.12262","article-title":"The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints","volume":"83","author":"SM Ahmed","year":"2014","journal-title":"Chem Biol Drug Des"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1128\/AAC.48.12.4687-4692.2004","article-title":"Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients","volume":"48","author":"AG Marcelin","year":"2004","journal-title":"Antimicrob Agents Chemother"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0149467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T02:43:37Z","timestamp":1692240217000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0149467"}},"subtitle":[],"editor":[{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0149467","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,1]]}}}